Alberico L. Catapano
University of Milan
740 Papers
5.6K Citations
Alberico L. Catapano is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 630 publications. Previous affiliations of Alberico L. Catapano include European Society of Cardiology & Baylor College of Medicine.
Chat about Author
Papers
LDL-C-lowering efficacy of the ezetimibe/simvastatin single tablet compared with atorvastatin or roslivastatin in elderly patients with hype rcholesterolemia
Nicola Abate,Christie M. Ballantyne,Alberico L. Catapano,Michael H. Davidson,W.E. Brady,Z. Yuan,Russell A. Gazzara,Andrew M. Tershakovec +7 more
- 01 Jan 2006
11
IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population.
Ashish Dhyani,G. Tibolla,Andrea Baragetti,Katia Garlaschelli,Fabio Pellegatta,Liliana Grigore,Giuseppe Danilo Norata,Alberico L. Catapano +7 more
TL;DR: The findings indicate that the N342S variant does not impact plasma lipid profile and is not associated with atherosclerosis progression and CVD in the general population, suggesting that other variants in the IDOL gene might be functionally linked with cholesterol metabolism.
Effect of partial ileal bypass on plasma clearance and binding of lipoproteins to liver membranes in the rabbit.
TL;DR: The in vivo data indicate that partial ileal bypass increases the fractional clearance rate (pools/h) of low density lipoproteins and the absolute catabolic rate from 0.495 to 0.605 mg/h, which may partly explain the hypocholesterolemic activity of partial ILEal by-pass.
11
The low density lipoprotein receptor: structure, function and pharmacological modulation.
TL;DR: La nature des recepteurs de lipoproteines LDL, les mieux caracterises des receptEurs Lipoproteiques, est discutee.
10
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category
Adam B. Polis,Nicola Abate,Alberico L. Catapano,Christie M. Ballantyne,Michael H. Davidson,Steven S. Smugar,M.P.H. Andrew M. Tershakovec +6 more
TL;DR: In these studies, CHD risk strata were inversely related to the likelihood of attaining NCEP LDL-C goals, but did not appear to affect the percentage cholesterol change from baseline, demonstrating the need for especially aggressive cholesterol lowering necessary to reach the lower cholesterol goal for high-risk patients.
10